XENETIC BIOSCIENCES, INC. Business Combination, Acquisition Related Costs
XENETIC BIOSCIENCES, INC. (XBIO) reported Business Combination, Acquisition Related Costs of $2.20 million for the 12-month period ending 2013-12-31, per its 10-K filed 2015-07-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2015-07-20
- XENETIC BIOSCIENCES, INC. business combination, acquisition related costs for fiscal 2013 was $2.20M.
- XENETIC BIOSCIENCES, INC. business combination, acquisition related costs for fiscal 2012 was $0.00.
| Period end | Business Combination, Acquisition Related Costs 12 month |
|---|---|
| 2013-12-31 | $2.20M 10-K · filed 2015-07-20 |
| 2012-12-31 | $0.00 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |